Table 2.
Main clinical outcomes
| Control (n = 72) | Prostacyclin (n = 72) | p-value | |
|---|---|---|---|
| PaO2/FiO2 ratio | |||
| Baseline |
123.6 ± 54.0 (111.0–136.2) |
123.2 ± 51.0 (11.3–135.0) |
0.96 |
| Day 5 |
208.6 ± 92.1 (186.9–230.4) |
227.9 ± 97.5 (204.7–251.1) |
0.24 |
| Difference Day 5—Baselinea |
85.0 ± 84.3 (65.0–105.0) |
104.7 ± 90.5 83.1–126.3) |
0.189* |
| Death at 90 days | 22 (31%, 20–42%) | 23 (32%, 21–44%) | |
| SOFA at day 7c | 9.0 ± 4.7 (7.7–10.3) | 8.6 ± 4.7 (7.3–9.9) | |
| SOFA at day 14d | 9.7 ± 5.7 (7.7–11.8) | 10.5 ± 5.1 (8.7–12.3) | |
| SOFA at day 28e | 10.8 ± 5.7 (7.1–14.4) | 8.8 ± 5.6 (5.6–12.0) | |
| Duration of ventilation | |||
| Including pauses in d | 11 (11–14, 8–14) | 11 (7–14, 9–14) | |
| ICU length of stay in d | 16 (10–34, 14–23) | 17 (12–43, 14–28) | |
| Ventilator associated pneumoniaf | 5 (7%, 2–15%) | 5 (7%, 2–16%) | |
| ICU acquired weaknessg | 7 (10%, 4–19%) | 4 (6%, 2–14%) | |
| Discharge locationh | |||
| Home | 20 (41%, 27–58%) | 19 (40%, 26–55%) | |
| Skilled nursing facility | 1 (2%, 0–11%) | 1 (2%, > 0–11%) | |
| Rehabilitation unit | 3 (6%, 1–17%) | 6 (13%, 5–25%) | |
| Other transfer unit | 25 (51%, 36–66%) | 22 (46%, 31–61%) | |
a142 patients included; c109 patients included; d65 patients included; e26 patients included; f143 patients included; g140 patients included; h97 patients included *p-value differs from baseline adjusted analysis (p = 0.177), Entries are mean ± SD, median interquartile range or absolute and percentage frequency, results in brackets are 95% CIs for the mean or Interquartile ranges and 95% CIs for the median or 95% CIs for proportions. Death at 90 days RR = 1.05 (95% CI 0.93–1.18), Risk difference = 1.4% (95% CI (− 13.8%)–(+ 16.5%)